LY411575, a potent γ‐secretase inhibitor, suppresses osteoclastogenesis in vitro and LPS‐induced calvarial osteolysis in vivo. Issue 11 (24th April 2019)

• Record Type: Journal Article
• Authors: Chen, Xinwei; Chen, Xuzhuo; Zhou, Zhihang; Qin, An; Wang, Yexin; Fan, Baoting; Xu, Weifeng; Zhang, Shanyong
• Is Part Of: Journal of cellular physiology. Volume 234:Issue 11(2019:Nov.)
• Page Start: 20944
• Page End: 20956
• Publication Date: 2019-04-24
• Subjects: LY411575 -- Notch -- osteoclast; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.28699
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: A series of osteolytic bone diseases are usually related to excessive bone resorption and osteoclast formation. Thus, agents or drugs which can target osteoclast development and attenuate bone loss are potentially considerable in preventing and treating of bone lytic diseases. In recent years, many studies have reported that Notch signaling has substantial impacts on the process of osteoclast differentiation, maturation, and bone destruction. In the present study, we showed that LY411575, a γ‐secretase inhibitor, could potently suppress osteoclast differentiation, osteoclast‐specific gene expression, and bone resorption via suppressing Notch/HES1/MAPK (ERK and p38)/Akt‐mediated NFATc1 induction in vitro. Consistent with in vitro results, LY411575 exhibited protective effects in lipopolysaccharides‐induced calvarial bone destruction in vivo. Collectively, these results indicate that LY411575 may have therapeutic potential in the treatment of osteoclast‐mediated osteolytic bone diseases. Abstract : In the present study, we showed that LY411575, a γ‐secretase inhibitor, could potently suppress osteoclast differentiation, osteoclast‐specific gene expression, and bone resorption via suppressing Notch/HES1/MAPK (ERK and p38)/Akt‐mediated NFATc1 induction in vitro. Consistent with in vitro results, LY411575 exhibited protective effects in lipopolysaccharides‐induced calvarial bone destruction in vivo. Collectively, these results indicate that LY411575 may have therapeutic potential in the treatment of osteoclast‐mediated osteolytic bone diseases.